WO2016063289A3 - Pharmaceutical tablet compositions comprising rifaximin - Google Patents

Pharmaceutical tablet compositions comprising rifaximin Download PDF

Info

Publication number
WO2016063289A3
WO2016063289A3 PCT/IN2015/000312 IN2015000312W WO2016063289A3 WO 2016063289 A3 WO2016063289 A3 WO 2016063289A3 IN 2015000312 W IN2015000312 W IN 2015000312W WO 2016063289 A3 WO2016063289 A3 WO 2016063289A3
Authority
WO
WIPO (PCT)
Prior art keywords
rifaximin
pharmaceutical tablet
tablet compositions
compositions
pharmaceutical
Prior art date
Application number
PCT/IN2015/000312
Other languages
French (fr)
Other versions
WO2016063289A2 (en
Inventor
Kumar Mohan
Kumar Anil
Dash Bidhubhusan
Original Assignee
Strides Arcolab Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Strides Arcolab Limited filed Critical Strides Arcolab Limited
Publication of WO2016063289A2 publication Critical patent/WO2016063289A2/en
Publication of WO2016063289A3 publication Critical patent/WO2016063289A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Disclosed herein is pharmaceutical tablet composition comprising Rifaximin and process for preparation thereof.
PCT/IN2015/000312 2014-10-22 2015-08-04 Pharmaceutical tablet compositions comprising rifaximin WO2016063289A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3379MU2014 2014-10-22
IN3379/MUM/2014 2014-10-22

Publications (2)

Publication Number Publication Date
WO2016063289A2 WO2016063289A2 (en) 2016-04-28
WO2016063289A3 true WO2016063289A3 (en) 2016-07-14

Family

ID=55761708

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000312 WO2016063289A2 (en) 2014-10-22 2015-08-04 Pharmaceutical tablet compositions comprising rifaximin

Country Status (1)

Country Link
WO (1) WO2016063289A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522895T3 (en) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. New polymorphic forms of rifaximin, procedures for their production and use in medicinal preparations
WO2015173697A1 (en) 2014-05-12 2015-11-19 Alfa Wassermann S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
EP4137132A1 (en) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
WO2020128583A1 (en) * 2018-12-19 2020-06-25 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090312357A1 (en) * 2006-09-22 2009-12-17 Cipla Limited Rifaximin
US20120245192A1 (en) * 2010-09-22 2012-09-27 Alfa Wassermann, S.P.A. Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease
US20130004576A1 (en) * 2010-03-05 2013-01-03 Alfa Wassermann S.P.A. Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect
US20140012001A1 (en) * 2010-09-13 2014-01-09 Sequent Scientific Ltd. Novel polymorphic form of rifaximin and process for its preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090312357A1 (en) * 2006-09-22 2009-12-17 Cipla Limited Rifaximin
US20130004576A1 (en) * 2010-03-05 2013-01-03 Alfa Wassermann S.P.A. Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect
US20140012001A1 (en) * 2010-09-13 2014-01-09 Sequent Scientific Ltd. Novel polymorphic form of rifaximin and process for its preparation
US20120245192A1 (en) * 2010-09-22 2012-09-27 Alfa Wassermann, S.P.A. Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VISCOUNT ET AL.: "Crystal founds of rifaximin and their effect on pharmaceutical properties", CRYST. ENG. COMM., vol. 10, July 2008 (2008-07-01), pages 1077 - 1078, XP009152378 *

Also Published As

Publication number Publication date
WO2016063289A2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
WO2016011222A3 (en) Circular polynucleotides
EP3139920A4 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
EP3641771A4 (en) Pharmaceutical compositions
EP3426348A4 (en) 3-desoxy derivative and pharmaceutical compositions thereof
HK1231416A1 (en) Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015191945A3 (en) Solid state forms of sofosbuvir
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
EP3133071A4 (en) C-aryl indican derivative, and pharmaceutical composition thereof, preparation method therefor and uses thereof
EP3582777A4 (en) Pharmaceutical composition of apixaban
AU2018302170A1 (en) Pharmaceutical compositions comprising entrectinib
PT3223796T (en) Pharmaceutical compositions, preparation and uses thereof
IL252897A0 (en) Indenyl compounds, pharmaceutical compositions, and medical uses thereof
EP3581183A4 (en) Tumor-treating pharmaceutical composition
EP3583943A4 (en) Pharmaceutical composition
EP3229791A4 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
EP3402470A4 (en) Stable pharmaceutical composition
EP3524250A4 (en) Pharmaceutical composition
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
EP3284743A4 (en) Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
EP3646867A4 (en) Pharmaceutical composition
EP3496714A4 (en) Drug compositions
EP3300474A4 (en) Betacryptoxanthin compositions, processes for preparation and uses thereof
EP3244895A4 (en) Novel pharmaceutical composition
EP3646863A4 (en) Pharmaceutical composition
EP3616722A4 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15852354

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15852354

Country of ref document: EP

Kind code of ref document: A2